Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770820 | 0.81 | CCNT1 (0.35) | PIM1PIM3PIM2 | |
| SCHEMBL19925706 | 0.80 | PIM1 (0.36) | PIM1WEE1PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL19925148 | 0.79 | PIM1 (0.35) | PIM1WEE1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23770818 | 0.75 | — | — | |
| SCHEMBL23770441 | 0.71 | HTR3E (0.43) | SLC6A4 | |
| SCHEMBL23770622 | 0.69 | CTSL (0.36) | PIM1 | |
| SCHEMBL5795727 | 0.67 | HTR3E (0.58) | PIM1WEE1PIM3PIM2SLC6A2 | |
| SCHEMBL19925230 | 0.65 | HTR3E (0.42) | — | |
| SCHEMBL23770460 | 0.65 | GSK3B (0.35) | WEE1PIK3CDPIK3CAPIK3CBSLC6A2 | |
| SCHEMBL23770450 | 0.64 | HTR3E (0.43) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |